JPH0196138A - Remedy for abnormal amniorrhexis - Google Patents
Remedy for abnormal amniorrhexisInfo
- Publication number
- JPH0196138A JPH0196138A JP62251778A JP25177887A JPH0196138A JP H0196138 A JPH0196138 A JP H0196138A JP 62251778 A JP62251778 A JP 62251778A JP 25177887 A JP25177887 A JP 25177887A JP H0196138 A JPH0196138 A JP H0196138A
- Authority
- JP
- Japan
- Prior art keywords
- fibrinogen
- rupture
- abnormal
- membranes
- amniorrhexis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 21
- 206010051641 Amniorrhexis Diseases 0.000 title abstract 3
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 31
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 31
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims description 27
- 108090000190 Thrombin Proteins 0.000 abstract description 6
- 159000000007 calcium salts Chemical class 0.000 abstract description 6
- 229960004072 thrombin Drugs 0.000 abstract description 6
- 102000009123 Fibrin Human genes 0.000 abstract description 5
- 108010073385 Fibrin Proteins 0.000 abstract description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 5
- 229950003499 fibrin Drugs 0.000 abstract description 5
- 239000008103 glucose Substances 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000001509 sodium citrate Substances 0.000 abstract description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract description 5
- 239000003381 stabilizer Substances 0.000 abstract description 4
- 108010039627 Aprotinin Proteins 0.000 abstract description 3
- 229960004405 aprotinin Drugs 0.000 abstract description 3
- 230000001112 coagulating effect Effects 0.000 abstract description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 230000003480 fibrinolytic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000003643 water by type Substances 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 description 26
- 239000002671 adjuvant Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 6
- 210000004381 amniotic fluid Anatomy 0.000 description 5
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001136 chorion Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔利用分野〕
本発明はフィプリノゲンを有効成分とする異常破水治療
剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Field of Application] The present invention relates to a therapeutic agent for abnormal water rupture containing fibrinogen as an active ingredient.
〔従来技術・発明が解決しようとする問題点〕血液に含
まれるフィプリノゲンは組織が創傷を受けたとき他の血
液成分と共に創傷面の毛細血管から流出してＭｉ繊織間
充填し、血液中のトロンビンと作用し合って不溶性のフ
ィブリンとなり、これが創傷面を膠着させる働きをもっ
ている。この膠着作用により創傷面に繊維芽細胞が発生
しやすくなり、これがやがて繊維細胞となって組織が固
定し、創傷面は治癒する。このように創傷の治癒に有効
なフィブリノゲンは乾燥フィプリノゲン（厚生省薬務局
監修、生物学的製剤基準）として医療に供されており、
静脈内投与によって低フィブリン血症の治療に使用され
ている。又、近年外科領域においては神経や微小血管等
の微細組織の吻合というように、極めて繊細な医術と使
用する薬剤の薬理作用の局所性の要求されるものが増え
、このような外科領域において微細組織の局所投与時に
強度の接着力をもつフィプリノゲン製剤（特開昭５７−
１４９２２９号公ｆｉｌ）も開発されている。[Prior art/problems to be solved by the invention] When tissue is injured, fibrinogen contained in blood flows out from the capillaries on the wound surface together with other blood components and fills between the Mi fibers, causing the It interacts with thrombin to form insoluble fibrin, which has the function of adhering the wound surface. This adhesive action facilitates the generation of fibroblasts on the wound surface, which eventually turn into fiber cells and fix the tissue, allowing the wound surface to heal. Fibrinogen, which is effective for wound healing, is provided medically as dried fibrinogen (supervised by the Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare, biological product standards).
It is used to treat hypofibrinemia by intravenous administration. In addition, in recent years in the surgical field, there has been an increase in the number of cases that require extremely delicate medical techniques and localized pharmacological effects of the drugs used, such as anastomosis of minute tissues such as nerves and microvessels. Fibrinogen preparation with strong adhesive force when locally administered to tissues
No. 149229 (fil) has also been developed.
一方、破水（胎胞破裂）とは、胎胞が破裂して羊水を流
出する症状である０分娩時における正常破水は、胎胞が
開口期陣痛の累積により緊張極度に達し内圧に耐えず破
裂し２０〜３０ｍ７の前羊水を流出する現象であり、通
常、外子宮口全量大（直径５ｃｍ以上）後に起こる。On the other hand, rupture of membranes (rupture of the fetal cyst) is a symptom in which the fetal vesicle ruptures and the amniotic fluid flows out. Normal rupture of membranes at the time of delivery is when the fetal vesicle becomes extremely tense due to the accumulation of open contractions and cannot withstand the internal pressure and ruptures. This is a phenomenon in which 20 to 30 m7 of amniotic fluid is shed, and it usually occurs after the external cervical os is completely enlarged (5 cm or more in diameter).
このような正常破水は分娩時に必須のものであるが、異
常破水、たとえば
１）前期破水：陣痛発来以前の破水、
２）早期破水：陣痛あるも外子宮口全量大前の破
゛水、
３）高位破水二子宮口より上位にて破水、４）偽羊水：
消失すべき絨毛膜と羊膜間の液体が分娩時まで残り、絨
毛膜の破裂により破水、５）羊水早漏：先退部が産道壁
に適合せず、後羊水まで破水、
６）遅滞破水：子宮口全量大するが強靭な卵膜の存する
場合に破水が遅延して被膜児を娩出することがある
においては、いずれも分娩経過が悪く、妊婦、胎児、新
生児に重篤な影響を与える。Such normal rupture of membranes is essential during childbirth, but abnormal rupture of membranes, such as 1) early rupture of membranes: rupture of membranes before the onset of labor, 2) early rupture of membranes: rupture of membranes before the external cervix is fully ruptured even though labor is in progress.
Water, 3) High rupture of membranes above the cervical os, 4) False amniotic fluid:
The fluid between the chorion and the amniotic membrane that should have disappeared remains until the time of delivery, and the membranes rupture due to rupture of the chorion. 5) Premature amniotic ejaculation: The anterior retraction part does not fit the birth canal wall, and the membranes rupture to the posterior amniotic fluid. 6) Delayed rupture of membranes: The uterus In cases where the entire mouth is large but strong egg membranes are present, the rupture of the membranes may be delayed and a encapsulated baby may be delivered. In both cases, the course of delivery is poor and has serious effects on the pregnant woman, fetus, and newborn.
従って、異常破水をより有効、かつ簡便に治療しうる薬
剤ないしは治療方法の開発が望まれている。Therefore, it is desired to develop a drug or treatment method that can more effectively and easily treat abnormal rupture of membranes.
本発明の目的は異常破水をより有効、かつ簡便に治療し
うる薬剤を堤供することである。An object of the present invention is to provide a drug that can more effectively and easily treat abnormal rupture of membranes.
本発明者は、上記目的、即ち異常破水をより有効、かつ
簡便に治療剤しうる薬剤を開発すべく種々研究を重ねて
きたところ、フィブリノゲンを存有効成分として局所投
与することにより、驚くべきことに多量の羊水の存在下
にもかかわらず、胎胞の破裂部分が接合されることを見
出して本発明を完成した。The present inventor has carried out various studies to achieve the above-mentioned purpose, that is, to develop a drug that can more effectively and easily treat abnormal membrane rupture. By locally administering fibrinogen as an active ingredient, the present inventors have discovered a surprising result. The present invention was completed by discovering that the ruptured part of the fetal fosicle can be joined despite the presence of a large amount of amniotic fluid.
本発明は、フィブリノゲンを有効成分とする異常破水治
療剤に関する。The present invention relates to a therapeutic agent for abnormal water rupture containing fibrinogen as an active ingredient.
本発明の異常破水治療剤は、フイプリノゲンよりなる主
剤に、必要に応して下記の補助剤等を配合したものであ
る。The therapeutic agent for abnormal water rupture of the present invention is a main ingredient consisting of fipurinogen, and the following auxiliary agents are blended as necessary.
本発明においてフイブリノゲンよりなる主剤におけるフ
イブリノゲンは厚生省薬務局監修の生物学的製剤基準（
１９７９年第２０１〜２０３頁）に従って製造された医
療用乾燥フィプリノゲンを使用することが好ましい。フ
ィブリノゲンよりなる主剤にはフィブリノゲン以外に、
安定化剤（たとえば、クエン酸ナトリウムなどの有ＪＩ
Ｊ、酸塩、ブドウ糖、グルコース、フルクトース、マン
ニットなどの単糖類など）、凝固性蛋白質などを配合し
てもよい、フィブリノゲンよりなる主剤の市販品としで
はフィブリノゲンーミドリ 〔■ミドリ十字〕の粉末が
ある。このものは乾燥フィブリノゲンに凝固性蛋白質及
び安定化剤としてクエン酸ナトリウム及びブドウ糖、グ
ルコース、フルクトース、マンニット等の単糖類を添加
したものである。In the present invention, fibrinogen in the main agent consisting of fibrinogen is based on the Biological Products Standards supervised by the Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare.
Preference is given to using dried medical fibrinogen prepared according to the following publication (1979, pp. 201-203). In addition to fibrinogen, the main agent is fibrinogen.
Stabilizers (e.g. sodium citrate, etc.)
Fibrinogen-Midori [■Midori Juji] powder is a commercially available product with the main ingredient consisting of fibrinogen, which may be blended with acid salts, monosaccharides such as glucose, glucose, fructose, mannitol, etc.), coagulating proteins, etc. There is. This product is made by adding coagulating protein and stabilizers such as sodium citrate and monosaccharides such as glucose, fructose, and mannitol to dried fibrinogen.
フィプリノゲンよりな゛る主剤、たとえばフィプリノゲ
ンーミドリは使用に際して水、たとえば注射用渾留水、
ｐＨ６〜７の低塩濃度緩衝液などに溶解させる。この低
塩濃度緩衝液としては０．０１〜０．０３モルのクエン
酸緩衝液が好適である。溶解温度は３２〜３６℃が好適
であり、溶解に際してフィプリノゲンを入れた瓶内の減
圧状態を維持することが好ましい。このような溶解条件
において乾燥フィプリノゲンの粉末は約１〜ＩＯＷ／Ｖ
％の範囲内で溶ける。A base agent consisting of fibrinogen, such as fibrinogen-midori, is used when using water, such as distilled water for injection.
Dissolve in a low salt concentration buffer solution with a pH of 6 to 7. As this low salt concentration buffer, a 0.01 to 0.03 molar citric acid buffer is suitable. The dissolution temperature is preferably 32 to 36°C, and it is preferable to maintain a reduced pressure state in the bottle containing fibrinogen during dissolution. Under these dissolution conditions, dry fibrinogen powder has a concentration of about 1 to IOW/V.
Soluble within % range.
また、本発明においては補助剤としてトロンビン、線溶
系酵素のインヒビクーあるいはカルシウム塩を用いるこ
ともできる。In the present invention, thrombin, fibrinolytic enzyme inhibitors, or calcium salts can also be used as adjuvants.
本発明において、補助剤を構成する線溶系酵素のインヒ
ビターとしてはアプロチニンなどが例示される。また、
カルシウム塩としては水溶液中でカルシウムイオンに解
離されるものであれば特に制限はなく、たとえば塩化カ
ルシウムなどが例示される。In the present invention, examples of fibrinolytic enzyme inhibitors constituting the adjuvant include aprotinin. Also,
The calcium salt is not particularly limited as long as it can be dissociated into calcium ions in an aqueous solution, and examples include calcium chloride.
さらに必要に応じて抗生物質、抗菌剤、抗炎症剤、止血
剤などを配合してもよい。Furthermore, antibiotics, antibacterial agents, anti-inflammatory agents, hemostatic agents, etc. may be added as necessary.
本発明における治療対象は、異常破水であるが、本発明
において特に治療対象とされるものは、胎胞破裂部を接
合することによって治癒される異常破水であり、従って
一般には正常破水より以前の段階で起こる異常破水、た
とえば前期破水、早期破水などの治療に有用である。The target of treatment in the present invention is abnormal rupture of membranes, but what is particularly targeted in the present invention is abnormal rupture of membranes, which can be cured by joining the ruptured part of the fetal membrane. It is useful in the treatment of abnormal membrane rupture that occurs at various stages, such as early rupture of membranes and early rupture of membranes.
本発明における異常破水治療剤の投与方法は、通常次の
通りである。即ち、上記のようにして調製されたフィプ
リノゲンよりなる主剤の水溶液を、適用部位に応じて、
局所的に注入する。補助剤を用いる場合は、主剤の投与
に次いで、あるいは当該主剤と同時にトロンビン、線溶
系酵素のインヒビターあるいはカルシウム塩よりなる補
助剤を適用部位に注入する。主剤と補助剤との同時投与
の場合には補助剤は予めフィプリノゲン溶解液に加えて
おいてもよい。The method of administering the therapeutic agent for abnormal water rupture in the present invention is usually as follows. That is, the aqueous solution of the main ingredient consisting of fibrinogen prepared as described above is applied to
Inject locally. When an adjuvant is used, the adjuvant consisting of thrombin, a fibrinolytic enzyme inhibitor, or a calcium salt is injected into the application site after or simultaneously with the administration of the main agent. In the case of simultaneous administration of the main agent and the adjuvant, the adjuvant may be added to the fibrinogen solution in advance.
投与量は濃度１〜ＩＯＷ／Ｖ％のフィプリノゲン溶液１
〜５ｆｆ＋！程度である。また、補助剤を用いる場合は
通常補助剤を等量使用する。ここに補助剤のそれぞれの
活性は、トロンビン１〜１００ｕ／ ｍｌ、アプロチニ
ン１００〜５０００ＫＩＥ／ｌ１１７、カルシウム塩１
０〜１００ｍＭである。投与回数としては４８時間間隔
で５〜１０回程度が例示される。The dosage is 1 fibrinogen solution with a concentration of 1 to IOW/V%.
~5ff+! That's about it. Further, when using an adjuvant, the adjuvant is usually used in an equal amount. Here, the respective activities of the adjuvants are thrombin 1-100 u/ml, aprotinin 100-5000 KIE/l 117, calcium salt 1
It is 0-100mM. An example of the number of administrations is about 5 to 10 times at 48 hour intervals.
本発明の異常破水治療剤はフィブリノゲンよりなる主剤
を胎胞の破裂部に投与することにより、また、必要に応
じて主剤の投与に次いでトロンビン、線溶製酵素のイン
ヒビター及びカルシウム塩よりなる補助剤を投与するか
、又は上記主剤と補助剤とを同時に投与することによっ
て、フィブリノゲンをフィブリンに転換させ、生成した
フィブリンが「糊」として接合作用を発揮し、破水部を
強固に接合して異常破水を治療するものである。The therapeutic agent for abnormal membrane rupture of the present invention is obtained by administering a main agent consisting of fibrinogen to the ruptured site of the fetal fosicle, and if necessary, following the administration of the main agent, an adjuvant agent consisting of thrombin, fibrinolytic enzyme inhibitor, and calcium salt is added. or by administering the above-mentioned main agent and adjuvant simultaneously, fibrinogen is converted to fibrin, and the generated fibrin exerts a bonding action as a "glue", firmly joining the ruptured area and preventing abnormal rupture of membranes. It is used to treat.
従って、本発明の異常破水治療剤は簡単な操作で、きわ
めて有効な異常破水治療効果を有するものである。Therefore, the therapeutic agent for abnormal water rupture of the present invention has an extremely effective therapeutic effect on abnormal water rupture with simple operation.
実施例１
コーンのエタノール画分Ｉから得たヒト・フィブリノゲ
ンを含む水溶液に及び安定化剤としてクエン酸ナトリウ
ムとブドウ糖を加え、除菌濾過および紫外線照射を施し
たのち、瓶に小分けして凍結乾燥し、Ｌ瓶中に医療用乾
燥フィプリノゲン１ｇ１クエン酸ナトリウム６００■、
フ゛ドウ零唐１６００■を含むフィプリノゲン製剤を得
る。Example 1 An aqueous solution containing human fibrinogen obtained from corn ethanol fraction I was added with sodium citrate and glucose as a stabilizer, subjected to sterile filtration and ultraviolet irradiation, and then divided into bottles and freeze-dried. In a L bottle, 1g of medical dry fibrinogen, 600ml of sodium citrate,
A fibrinogen preparation containing Fido Zero Tang 1600 is obtained.
使用時にはこのフィブリノゲン製剤を入れた瓶に注射器
で日周注射用蒸留水５０ｍ７を注入して瓶内の減圧状態
を維持し、瓶を３２〜３６℃に加温して約２０分間振と
うし、粘稠で澄明なフィブリノゲン溶液を調製し、これ
を注射器内へ移して局所投与に供する。When in use, inject 50 m7 of distilled water for diurnal injection into the bottle containing this fibrinogen preparation with a syringe, maintain the vacuum inside the bottle, warm the bottle to 32-36°C, and shake for about 20 minutes. A viscous, clear fibrinogen solution is prepared and transferred into a syringe for topical administration.
臨床例１ 異常破水を起こした患者は１１名である。Clinical case 1 There were 11 patients who experienced abnormal rupture of their membranes.
これら患者に対して、実施例１に準じて調製したフィブ
リノデフ２％溶液２ｍｌを破水の生じている胎胞局所に
４８時間間隔で５〜ｌＯ回投与したところ８例に治療効
果（著効２例、有効６例）が認められた。To these patients, 2 ml of a 2% Fibrinodef solution prepared according to Example 1 was administered 5 to 10 times at 48-hour intervals to the fetal area where the membranes had ruptured, resulting in a therapeutic effect in 8 cases (significant response in 2 cases). , effective in 6 cases).
−告
手３ダＥ（甫正占（自発）
■、事件の表示
昭和６２年特許願第２５１７７８号
２、発明の名称
異常破水治療剤
３、補正をする者
事件との関係 特許出願人
氏名（名称） 株式会社 ミドリ十字
４、代理人■５４１
住所 大阪市東区平野町４丁目５６番地（湯水ビル）
狙 （０６） ２２７−１１５６
明細書の「発明の詳細な説明」の欄
６、補正の内容
（１１明細書第３真下から第２行の「治療剤」を「治療
」に訂正する。- Complainant 3 DaE (Ho Zheng Zhan (spontaneous)) ■, Indication of the case, Patent Application No. 251778 of 1988, 2, Title of the invention: Abnormal water rupture treatment agent 3, Person making the amendment, Relationship with the case, Patent applicant name ( Name) Midori Juji Co., Ltd. 4, Agent ■541 Address 4-56 Hirano-cho, Higashi-ku, Osaka (Yusui Building) Aim (06) 227-1156 Column 6 of “Detailed Description of the Invention” of the specification, Contents of amendment ("Therapeutic agent" in the second line from the bottom of No. 11 Specification is corrected to "therapy."
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62251778A JP2526073B2 (en) | 1987-10-06 | 1987-10-06 | Abnormal rupture treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62251778A JP2526073B2 (en) | 1987-10-06 | 1987-10-06 | Abnormal rupture treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0196138A true JPH0196138A (en) | 1989-04-14 |
| JP2526073B2 JP2526073B2 (en) | 1996-08-21 |
Family
ID=17227783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62251778A Expired - Fee Related JP2526073B2 (en) | 1987-10-06 | 1987-10-06 | Abnormal rupture treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2526073B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55110557A (en) * | 1979-02-15 | 1980-08-26 | Immuno Ag | Tissue adhesive and its preparation |
| JPS57149229A (en) * | 1981-03-13 | 1982-09-14 | Green Cross Corp:The | Frozen fibrinogen preparation |
| JPS5953428A (en) * | 1982-08-19 | 1984-03-28 | ベ−リングヴエルケ・アクチエンゲゼルシヤフト | Low temperature pasteurzed human fibrinogen and manufacture |
-
1987
- 1987-10-06 JP JP62251778A patent/JP2526073B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55110557A (en) * | 1979-02-15 | 1980-08-26 | Immuno Ag | Tissue adhesive and its preparation |
| JPS57149229A (en) * | 1981-03-13 | 1982-09-14 | Green Cross Corp:The | Frozen fibrinogen preparation |
| JPS5953428A (en) * | 1982-08-19 | 1984-03-28 | ベ−リングヴエルケ・アクチエンゲゼルシヤフト | Low temperature pasteurzed human fibrinogen and manufacture |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2526073B2 (en) | 1996-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5951583A (en) | Thrombin and collagen procoagulant and process for making the same | |
| Hamilton et al. | Effects of parenteral hyperalimentation on upper gastrointestinal tract secretions | |
| US6825323B2 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same | |
| Cliffton et al. | Lysis of thrombi produced by sodium morrhuate in the femoral vein of dogs by human plasmin (fibrinolysin) | |
| US5364622A (en) | Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel | |
| PT87658B (en) | Process for the preparation of a solution with high specific volumic activity of a protein with a plasticizer activator activity of the tissues | |
| US5578305A (en) | Methods and preparations for preventing adhesions to organs and parts of organs | |
| DK174978B1 (en) | Use of Human Coagulation Factor XIII for the Preparation of a Drug to Prevent Intraventricular Bleeding in Premature Infants | |
| CA2091134C (en) | Therapeutic agent for threatened abortion | |
| McGraw et al. | Sucralfate | |
| JPH0196138A (en) | Remedy for abnormal amniorrhexis | |
| CN107648598B (en) | A kind of pharmaceutical composition for treating acute ischemic cerebral apoplexy | |
| US20240066106A1 (en) | Haemorrhage inhibiting compositions and methods involving the same | |
| AU2001227771B2 (en) | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen | |
| RU2177789C2 (en) | Drug favoring ripening of cervix of the uterus, method for accelerating ripening of cervix of the uterus, and device for transportation of drug to the cervix of the uterus | |
| RU2142271C1 (en) | Method of prophylaxis of local and general postischemic complications in long-standing compression injury to extremity | |
| US20200376097A1 (en) | Pharmaceutical composition, use and method for fistula treatment in children | |
| SU1736496A1 (en) | Method for treating endometritis | |
| JPH027930B2 (en) | ||
| JP3028274B2 (en) | Stabilization method of thrombin solid preparation | |
| DIVELEY et al. | Chemotherapy in infections of the bones and soft tissues | |
| RU2204336C2 (en) | Method for stopping nasal hemorrhage | |
| WO2024042148A1 (en) | Haemorrhage inhibiting compositions and methods involving the same | |
| SU1215673A1 (en) | Method of treatment of acute pancreatitis | |
| Nakajima et al. | Clinical Evaluation of W14859 (Liquid Thrombin) on Upper Gastro-Intestinal Haemorrhage–Comparative Study of W14859 versus Topical Thrombin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |